anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To newly obtain high purity bacampicillin with a high yield by allowing ampicillin to react with a β-diketone, allowing the resultant enamine to react with a specified compd. in the presence of a catalyst and hydrolyzing the resultant ester in an acidic medium.  
     CONSTITUTION: Ampicillin preferably in the form of an alkaline salt is allowed to react with a compd. of the formula R 1 COCHR 2 COR 3  [where R 1  is a 1-4C alkyl, (substd.) aryl, etc.; R 2  is H, a 1-4C alkyl, etc.; and R 3  is a 1-4C alkyl, (substd.) aryl, etc.] at 0-60°C for 2-8 hr in an aprotic polar solvent in the presence of an org. base, etc. The resultant compd. of formula I (where X is an alkali metal, an org. base, etc.) is allowed to react with a compd. of formula II (where Z is Cl or I) in a solvent such as acetone in the presence of a catalyst such as a quat. ammonium salt. The resultant compd. of formula III is hydrolyzed in an acidic medium to obtain the objective compd. of formula [V, e.g. 1-ethoxycarbonyloxyethyl 6-(D-(-)α-amino-α-phenylacetamido)penicillanate. 
     COPYRIGHT: (C)1993,JPO
Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
The invention provides moistening balsam. The formula comprises the following raw materials in parts by weight: 12.0 parts of glycosidic amino stearate, 5.0 parts of propylene glycol, 10.0 parts of cetyl alcohol lactate, 3.0 parts of cetyl alcohol lactate 60, 5.0 parts of white liquid paraffin, 59.0 parts of deionized water, 2.5 parts of polyethylene glycol of cetyl stearyl alcohol, 2.5 parts of preservative (Dowicil200), 1.0 part of cetyl alcohol and defined amount of essence. The raw materials have synergistic effects in dosages and physicochemical properties, thus achieving the skin moistening and protecting effects. The PH value of the moistening balsam is close to the PH values of human skins, so that the moistening balsam is non-irritant to skins. Users obviously feel comfortable, soft and moist after using the moistening balsam. The moistening balsam has obvious moistening, softening and lubricating effects.
FIELD: cosmetology. SUBSTANCE: hair care balsam containing EDTA disodium salt, water comprises additionally keropeptide, vegetable extracts, polybasic alcohols, surface-active substance, essential oils, nipagin and nipasol. Components are taken in the definite quantitative ratio. Balsam promotes to uniform hair growth, gives luster and elasticity. EFFECT: enhanced and valuable properties of balsam. 4 cl, 2 tbl, 2 ex
Risk Summary

PROCRIT from multiple-dose vials contains benzyl alcohol and is contraindicated in lactating women [see Contraindications (4), Warnings and Precautions (5.9)] . Advise a lactating woman not to breastfeed for at least 2 weeks after the last dose. The preservative benzyl alcohol has been associated with serious adverse reactions and death when administered intravenously to neonates and infants [see Use in Specific Populations (8.4)]. There is a potential for similar risks to infants exposed to benzyl alcohol through human milk. 

Do not mix PROCRIT with bacteriostatic saline containing benzyl alcohol, if administering PROCRIT to a lactating woman [see Dosage and Administration (2.1)] . 

There is no information regarding the presence of PROCRIT in human milk, the effects on the breastfed infant, or the effects on milk production. However, endogenous erythropoietin is present in human milk. Because many drugs are present in human milk, caution should be exercised when PROCRIT from single-dose vials is administered to a lactating woman.
ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
Intervertebral disc degeneration (IVDD) stands as the primary cause of low back pain (LBP). A significant contributor to IVDD is nucleus pulposus cell (NPC) senescence. However, the precise mechanisms underlying NPC senescence remain unclear. Monoacylglycerol lipase (MAGL) serves as the primary enzyme responsible for the hydrolysis of 2-arachidonoylglycerol (2-AG), breaking down monoglycerides into glycerol and fatty acids. It plays a crucial role in various pathological processes, including pain, inflammation, and oxidative stress. In this study, we utilized a lipopolysaccharide (LPS)-induced NPC senescence model and a rat acupuncture-induced IVDD model to investigate the role of MAGL in IVDD both in vitro and in vivo. Initially, our results showed that MAGL expression was increased 2.41-fold and 1.52-fold within NP tissues from IVDD patients and rats induced with acupuncture, respectively. This increase in MAGL expression was accompanied by elevated expression of p16INK4α. Following this, it was noted that the suppression of MAGL resulted in a notable decrease in the quantity of SA-β-gal-positive cells and hindered the manifestation of p16INK4α and the inflammatory factor IL-1β in NPCs. MAGL inhibition promotes type II collagen (Col-2) expression and inhibits matrix metalloproteinase 13 (MMP13), thereby restoring the balance of extracellular matrix (ECM) metabolism both in vitro and in vivo. A significant role for STING has also been demonstrated in the regulation of NPC senescence by MAGL. The expression of the STING protein was reduced by 57% upon the inhibition of MAGL. STING activation can replicate the effects of MAGL and substantially increase LPS-induced inflammation while accelerating the senescence of NPCs. These results strongly indicate that the inhibition of MAGL can significantly suppress nucleus pulposus senescence via its interaction with STING, consequently restoring the balance of ECM metabolism. This insight provides new perspectives for potential treatments for IVDD.
In the control group, no application was performed during this period, and routine medical treatments were continued. The training group was evaluated before and after the training, while the control group was re-evaluated at the end of the 6th week after the first evaluation. After the study was completed, the volunteers from the control group were also given training.
This is a randomized withdrawal, double blind, placebo controlled study of pediatric subjects (2 to \<18 years of age) with JIA. The primary objective is to compare the efficacy of tofacitinib versus placebo for the treatment of signs and symptoms of JIA at Week 26 of the double blind phase as measured by the percentage of subjects with disease flare (according to PRCSG/PRINTO Disease Flare criteria) after Week 18 of the open label run in phase.All eligible subjects enrolled in the study will initially receive open label tofacitinib for 18 weeks (run in phase). At the end of the 18 week run in phase, only subjects who achieve at least a JIA ACR 30 response will be randomized to the 26 week double blind, placebo controlled phase. Subjects who do not achieve a JIA ACR 30 response at this time point will be discontinued from the study. In addition, subjects who experience a single episode of disease flare at any time during the study (including the open label run in and double blind phase) will also be discontinued from the study. All subjects participating in this study, including those discontinued from the study, will have the option, if eligible (based on inclusion and exclusion criteria), of enrolling in the tofacitinib JIA long term extension study (A3921145).

Subjects who are eligible for the 26 week double blind phase will be randomized (1:1 ratio) to either active tofacitinib or placebo. For subjects with polyarticular course JIA (ie, extended oligoarthritis, polyarthritis RF+, polyarthritis RF , systemic JIA with active arthritis but without active systemic features), randomization will be stratified by JIA category and baseline CRP (normal, above normal). For subjects with psoriatic and enthesitis related arthritis, randomization will be stratified by JIA category.

Approximately 210 subjects will be enrolled in the open label run in phase. Among subjects with polyarticular course JIA, stratification will target at least 50% with a baseline CRP above the upper limit of normal. The first cohort (ie, polyarticular course JIA) will have at least 170 subjects enrolled in the run in phase with the minimum number of JIA categories as follows: 24 with extended oligoarthritis, 20 with polyarthritis RF+, 62 with polyarthritis RF-, and no minimum for subjects with systemic JIA with active arthritis but without active systemic features. Additional cohorts (ie, psoriatic and enthesitis related arthritis) will include a minimum of 20 subjects with psoriatic arthritis, and 20 subjects with enthesitis related arthritis. The overall target minimum number of subjects to be enrolled in the study by age is as follows: 20 subjects 2 to \<6 years, 20 subjects 6 to \<12 years, and 20 subjects 12 to \<18 years. The duration of subject participation among those who complete the study (without discontinuation) is expected to be approximately 44 weeks.
The use of single-walled carbon nanotubes (SWCNTs) in biomedical applications is limited due to their inability to disperse in aqueous solutions. In this study, dispersed -COOH functionalized CNTs with N-succinylated chitosan (CS), greatly increasing the water solubility of CNTs and forming a uniformly dispersed nanocomposite solution of CNTs@CS. Coupling reagent EDC/NHS was used as a linker with the -COOH groups present on the N-succinylated chitosan which significantly improved the affinity of the CNTs for biomolecules. Myoglobin (Mb) is a promising biomarker for the precise assessment of cardiovascular risk, type 2 diabetes, metabolic syndrome, hypertension and several types of cancer. A high level of Mb can be used to diagnose the mentioned pathogenic diseases. The CNTs@CS-FET demonstrates superior sensing performance for Mb antigen fortified in buffer, with a wide linear range of 1 to 4000 ng/mL. The detection limit of the developed Mb immunosensor was estimated to be 4.2 ng/mL. The novel CNTs@CS-FET immunosensor demonstrates remarkable capability in detecting Mb without being affected by interferences from nonspecific antigens. Mb spiked serum showed a recovery rate of 100.262 to 118.55 % indicating great promise for Mb detection in clinical samples. The experimental results confirmed that the CNTs@CS-FET immunosensor had excellent selectivity, reproducibility and storage stability.
Examples described herein generally relate to a system and methods for registering a user with an online service. An application server receives, from a health care provider, first patient identifying information and second patient identifying information for a new account. The server transmits a message to the patient based on the second patient identifying information, the message including a unique access code for the patient. The server receives, from a client application via a secure link, a user access code and user identifying information. The server verifies that the user access code matches the unique access code and the user identifying information matches the first patient identifying information. The server requests, in response to the verifying, a new username and password via the client application. The server associates the new username and password with the new account, the online service, the first and second patient identifying information.
PROBLEM TO BE SOLVED: To provide an efficient at-home medical treatment system shortening time required for diagnosing a patient. SOLUTION: The biological information of the patient is sampled by a biological inspector and the biological information is transmitted through a transmitter/ receiver 2, terminal adapter 3, DSU 4 and digital public line network 5 to a medical treatment center together with the identification number of the patient. At the medical treatment center, the value of biological information is cumulatively stored in a data processor 9 corresponding to the identification number. The inspected results and the history of diseases of the patient in the past are stored in a data base 10 corresponding to the identification number of the relevant patient. It is discriminated by the data processor 9 whether the latest value of biological information is settled within the range of values decided in advance or not.  When it is discriminated that the latest value of biological information gets out of the range of values decided in advance, the identification number transmitted together with this biological information, the value of biological information stored corresponding to this identification number, the inspected results and the history of diseases in the past stored corresponding to this identification number are displayed on a display 11.
Provided herein are systems and methods for dynamically providing messages based on indications of states to users at risk of migraines. A server can maintain, on a database, an identification of a set of activities for users at risk of migraines, with each activity having a set of messages to be presented in accordance with a rule. The server can receive, via a user interface, an indication identifying a state of the user associated with the migraine. The server can select, based on the state of the user identified in the response, an activity to provide to the user for the session. The server can identify, in accordance with the rule for the activity, a message from the set of messages. The server can cause the message identifying the activity to be presented via the user interface.
BACKGROUND: Rs1333040 is the single-nucleotide polymorphisms (SNP) related with coronary heart disease (CHD). The aim of the present study is to examine the association between rs1333040 polymorphism genotypes and CHD and to further explore the molecular mechanism in Chinese population.
METHODS: A case-control study was used in this study, including 500 CHD patients and 500 control subjects. CHD patients and controls were distinguished by coronary angiography. Genotypes of rs1333040 were determined on the Agena MassARRAY system. Statistical analysis was conducted by SPSS (Ver 16.0) and plink (Ver. 1.07, Shaun Purcell).
RESULTS: Fisher's exact test by plink indicated a significant difference in the allele distribution between cases and controls, the allele T may be associated with a higher risk of CHD (p = 0.012, odds ratio (OR) = 1.258). The serum levels of low-density lipoprotein cholesterol (LDL-C) (p = 0.029) and Gensini score (p = 0.008) distributed differently in patients with various alleles. In the recessive model, the levels of high-density lipoprotein (HDL) and apolipoprotein A (ApoA) were higher in the TC + CC genotype than in the TT genotype. The TC + TT genotype was found to be risk factors against CHD in a dominant model (OR = 1.278, p = 0.014). The TC + TT genotype along with multiple risk factors significantly positively correlated with the risk of CHD.
CONCLUSIONS: The present study investigates the association between the rs1333040 polymorphism genotypes and CHD. The T allele of rs1333040 is the susceptibility site of CHD. The interaction between SNP and various risk factors plays an important role in the development of CHD.
The present invention relates to a method for preparing kidney-reinforcing and health-preserving soymilk tablets with micron antler powder, micron tortoise plastron powder, micron curculigo rhizome powder, micron walnut kernel powder, micron polygonatum powder, micron ganoderma powder and micron dodder powder. The kidney-reinforcing and health-preserving soymilk tablets are formed by that the micron antler powder, the micron tortoise plastron powder, the micron curculigo rhizome powder, the micron walnut kernel powder, the micron polygonatum powder, the micron ganoderma powder, the micron dodder powder and xylitol raw material through high-technology airflow superfine grinding processing are added into various traditional soymilk tablets and combined and processed. The kidney-reinforcing and health-preserving soymilk tablets have obvious functions of reinforcing kidneys and preserving health and also have the effects of allaying fatigue, enhancing immunity, etc. Middle-aged people and old people who have kidney deficiency and general deficiency can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and simultaneously, the present invention strengthens the health-care functions of benefiting the heart qi, strengthening the middle-jiao, increasing intelligence, benefiting essential qi, strengthening muscles and bones, beautifying faces, etc. because the ingredient of the micro ganoderma powder which is extolled as orient immortal grass. Therefore, the present invention is a favorable method for preparing the kidney-reinforcing and health-preserving soymilk tablets for health care and longevity, the kidney-reinforcing and health-preserving soymilk tablets have Chinese characteristics and are especially designed for the middle-aged people and the old people who have the kidney deficiency and the general deficiency.
OBJECTIVE: Teachers are the most common occupational group reporting to the voice clinics with dysphonia across the globe. However, less is known about teachers' perceptions about their voice and voice problems. Hence the present study aimed to explore teachers' perception about their teaching voice, voice problems and vocal health-seeking behaviors.
METHOD: A qualitative phenomenological research design using semi-structured interviews were conducted with fifteen female primary school teachers. Participants were asked to express their perception of teaching voice, vocal health care knowledge, and vocal hygiene practices. Using inductive analysis, the researchers converted the raw data into concepts or themes and discussed.
RESULT: The present study results showed that teachers perceive voice as the primary tool for their profession. However, teachers consider voice problems as part of their professional commitments. Despite knowing the harmful effects of voice problems, teachers' pay less attention to their voice problems and perceive them as usual, unavoidable and part of their profession. Due to their demanding work schedule and not getting enough support from the management, they hesitate to consult medical professionals unless it severely affects them.
CONCLUSIONS: The data obtained from this study can be used to improve the teachers' knowledge regarding vocal health and convince the school management to extend their support for the successful implementation of the vocal health training programs for teachers.
Female patients of childbearing age should be told about the consequences of exposure to trandolapril tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. 

NOTE: As with many other drugs, certain advice to patients being treated with trandolapril tablets are warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
The invention provides a selenium-rich cardamine violifolia extract which is extracted from aerial part stems and leaves of cardamine violifolia, and the extraction steps comprise: the dried stem and leaf of the overground part of cardamine violifolia which is rich in selenium is crushed, added with clear water for leaching, and filtered to obtain filter residue and filtrate. Extracting the filter residue again under the same conditions, and filtering to obtain filter residue and filtrate. Mixing the filtrates, and concentrating to obtain concentrated solution. Adding ethanol into the concentrated solution, precipitating with ethanol, and standing overnight. And filtering and separating the liquid phase and the solid phase after alcohol precipitation. Dissolving the solid phase in water, adding ethanol, precipitating with ethanol, and standing overnight. And filtering and separating the liquid phase and the solid phase after alcohol precipitation, and drying the solid phase to obtain the target product. The total selenium content in the selenium-enriched cardamine violifolia extract reaches more than 2800mg/kg by adopting a two-step alcohol precipitation method, wherein the organic selenium content reaches more than 97%. Furthermore, the invention also provides application of the selenium-rich cardamine violifolia extract in liver protection, the curative effect is obvious, the selenium-rich cardamine violifolia extract can be used for developing series functional foods, and the application range is wide.
INTRODUCTION: Obesity is a chronic condition associated with low-grade inflammation mainly due to immune cell infiltration of white adipose tissue (WAT). WAT is distributed into two main depots: subcutaneous WAT (sWAT) and visceral WAT (vWAT), each with different biochemical features and metabolic roles. Proinflammatory cytokines including interleukin (IL)-16 are secreted by both adipocytes and infiltrated immune cells to upregulate inflammation. IL-16 has been widely studied in the peripheral proinflammatory immune response; however, little is known about its role in adipocytes in the context of obesity.
AIM & METHODS: We aimed to study the levels of IL-16 in WAT derived from sWAT and vWAT depots of humans with obesity and the role of this cytokine in palmitate-exposed 3T3-L1 adipocytes.
RESULTS: The results demonstrated that IL-16 expression was higher in vWAT compared with sWAT in individuals with obesity. In addition, IL-16 serum levels were higher in patients with obesity compared with normal-weight individuals, increased at 6 months after bariatric surgery, and at 12 months after surgery decreased to levels similar to before the intervention. Our in vitro models showed that IL-16 could modulate markers of adipogenesis (Pref1), lipid metabolism (Plin1, Cd36, and Glut4), fibrosis (Hif1a, Col4a, Col6a, and Vegf), and inflammatory signaling (IL6) during adipogenesis and in mature adipocytes. In addition, lipid accumulation and glycerol release assays suggested lipolysis alteration.
DISCUSSION: Our results suggest a potential role of IL-16 in adipogenesis, lipid and glucose homeostasis, fibrosis, and inflammation in an obesity context.
Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.